Abstract
Introduction/objectivesTo evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA).MethodsPatients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (n=239) at Weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at Weeks 24, 28, then q8w through Week 52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) was assessed. Relationships between these outcomes and disease activity and patient functional capability were evaluated post hoc.ResultsAt Week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (−2.91 vs −0.71), and WLQ productivity loss score (−2.92 vs −0.78) was greater in the golimumab group versus the placebo group, respectively. At Week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: −2.89 and −3.31; WLQ productivity loss: −4.49 and −3.28, respectively). HRQoL and productivity were generally associated with disease activity and functional capability, with continued association from Week 8 through Week 52.ConclusionIV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability.Key Points• In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year• Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes• IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity
Highlights
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, spondylitis, psoriatic skin lesions, and nail psoriasis [1]
The data presented here demonstrate that reducing disease activity has a positive impact on health-related quality of life (HRQoL); daily productivity at work, school, or home; and productivity at work in patients with psoriatic arthritis (PsA) that is maintained through 1 year
As expected based on previous results in this patient population [14,15,16], in patients with active PsA, treatment with IV golimumab resulted in improvements in EQ-5D-5L index, EQ-VAS, daily productivity VAS, and Work Limitations Questionnaire (WLQ) productivity loss score as early as Week 8 that were maintained through Week 52
Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, spondylitis, psoriatic skin lesions, and nail psoriasis [1]. Work productivity, as measured by the Work Limitations Questionnaire (WLQ), was reduced by 7% in patients with PsA compared with benchmark employees without limitations [10]. In another multinational, real-world PsA population, the presence of enthesitis, dactylitis, inflammatory back pain, or sacroiliitis was significantly associated with worse patient quality of life and/or work productivity as measured by the EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS) and the work productivity and activity index [13]. An important goal of PsA treatment is improved HRQoL and productivity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
